browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
0cfc5814-9568-4ac7-9b4e-10ef24e5f391
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 00:46:52
Income (reported)
$50,000
Expenses (reported)
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

CAPITOL COUNSEL LLC

Government affairs.

Contact
TRACEY A. GRAY
Phone
+1 202-861-3200
Address
zip:20005, city:Washington, state:DC, street:700 13th Street NW, 2nd Floor
Client

GENENTECH

State
DC
Country
US
Government-entity client
false
Effective date
2007-08-13
Issues lobbied + lobbyists (2)

MMM — Medicare/Medicaid

Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.

Lobbyists:
  • SHANNON FINLEY
  • JEFFREY CARROLL
  • mr CHARLES PATRICK MICHAELS
  • ANN JABLON — covered position: Chief of Staff, Rep. Richard E. Neal; Legislative Director, Rep. Richard E. Neal; Administrative Assistant, Rep. Richard E. Neal; Executive/ Legislative Assistant, Rep. Richard E. Neal. [new]
  • JOHN MARTIN — covered position: Principal Associate Commissioner, FDA; Legislative Director, Sen. Tom Cotton; Legislative Assistant; Sen. Tom Cotton; Legislative Assistant, Representative Tom Cotton. [new]

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

HCR — Health Issues

340B Program issues and patient access to pharmaceuticals. Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains. Enhanced FDA reporting and risk mitigation plans for certain medicines. Incentives for antimicrobial and antiviral research, medical countermeasures, and novel product development.

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.